MedTrace Logo

Amniotic Fluid Mesenchymal Stem Cells Developed for Chondrogenic Treatment (AFCC) Injection in Elderly Knee Osteoarthritis Patients

NCT06386679 · Status: ENROLLING_BY_INVITATION · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2024-04-26

No results posted yet for this study

Summary

Amniotic fluid mesenchymal stem cells developed for chondrogenic treatment (AFCC) are used to treat elderly patients suffering from knee osteoarthritis (OA). The injection reduces inflammation and promotes the recovery of knee function, leading to an improved quality of life.

Conditions

Interventions

BIOLOGICAL

allogenic amniotic fluid mesenchymal stem cell

Intra-articular AFCC injection will be given for single knee for each patient in single dose, 20 million of AFCC in each dose

Sponsors & Collaborators

  • Siriraj Hospital

    lead OTHER

Principal Investigators

  • Tatsanee Phermthai, PhD. · Siriraj Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
60 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-17
Primary Completion
2023-11-23
Completion
2025-03-31

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06386679 on ClinicalTrials.gov